{"product_id":"imaging-and-focal-therapy-of-early-prostate-cancer-9783031667534","title":"Imaging and Focal Therapy of Early Prostate Cancer","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003ePart I.  Why Consider Focal Therapy?.- 1. \u003c\/b\u003eWhat is Focal Therapy for Prostate Cancer? A Guide for Patients\u003cb\u003e.-\u003c\/b\u003e 2. Evolution of Focal Therapy for Localized Breast Cancer: Lumpectomy\u003cb\u003e.-\u003c\/b\u003e 3. Image-targeted Therapy for Localized Kidney Cancer\u003cb\u003e.-\u003c\/b\u003e 4. The Patient's Perspective: What Does the Patient Want?\u003cb\u003e .-\u003c\/b\u003e \u003cb\u003ePart II. Global Perspective of Active Surveillance (AS) and Focal Therapy (FT) .-\u003c\/b\u003e\u003cb\u003e \u003c\/b\u003e5. Intersection of AS and Radical Therapy: Opportunities for FT in North America.\u003cb\u003e.- \u003c\/b\u003e6. FT and AS of Prostate Cancer - A European Perspective\u003cb\u003e.- \u003c\/b\u003e7. FT and AS of Prostate Cancer in Southeast Asia and the East\u003cb\u003e.- \u003c\/b\u003e8. FT Perception and Acceptance in South America\u003cb\u003e.- \u003c\/b\u003e\u003cb\u003ePart III.  The Focal Therapy Concept: Scientific Foundation.-\u003c\/b\u003e\u003cb\u003e \u003c\/b\u003e9. Understanding Tumor Biology and Pathology - Cancer Grade, Volume, and Spatial Location  as a Foundation for Focal Therapy\u003cb\u003e.-\u003c\/b\u003e 10. Identifying and Characterizing the Index Lesion\u003cb\u003e.- \u003c\/b\u003e11. The Role of Molecular Techniques to Distinguish Low Grade from Lethal Cancers\u003cb\u003e.- \u003c\/b\u003e12. Utilizing Biopsy-based Genomic Assays to Risk Stratify Patients for Active Treatment\u003cb\u003e.- \u003c\/b\u003e13.  Can Understanding and Utilizing the Tumor Microenvironment Enhance the Therapeutic Efficacy of FT?\u003cb\u003e .-\u003c\/b\u003e 14. Differences between MRI Visible vs Invisible Cancers: Biology and Outcomes\u003cb\u003e.- \u003c\/b\u003e\u003cb\u003ePart IV.  Prostate Imaging and Staging.-\u003c\/b\u003e\u003cb\u003e \u003c\/b\u003e15. PIRADS Reporting Standards and Limitations for Cancer Detection in the Peripheral Zone vs Transition Zone, PI-QUAL, and Standardization in MR Quality\u003cb\u003e.-\u003c\/b\u003e 16. Employing a Quality Improvement Program to Optimize mpMRI-directed Fusion Biopsy\u003cb\u003e.-\u003c\/b\u003e 17. Multiparametric Ultrasound for Prostate Imaging and Targeting\u003cb\u003e.-\u003c\/b\u003e 18. What is Necessary for FT Staging: Cross-sectional vs PET vs Nil?\u003cb\u003e.-\u003c\/b\u003e \u003cb\u003ePart V.  Image-Targeted Prostate Biopsy Techniques.-\u003c\/b\u003e\u003cb\u003e \u003c\/b\u003e19. mpMRI-TRUS Prostate Fusion Biopsy Commercial Systems\u003cb\u003e.-\u003c\/b\u003e20. Comparison of Outcomes with Transperineal vs Transrectal Image-targeted Prostate Biopsy\u003cb\u003e.- \u003c\/b\u003e21. Using Multicore, Transperineal Prostate Mapping Biopsy to Detect, Localize and Treat the mpMRI Invisible Lesion\u003cb\u003e.- \u003c\/b\u003e22. Multi-parametric Ultrasound (mpUS) Biopsy\u003cb\u003e.-\u003c\/b\u003e 23. Diagnostic Performance of PET-based Targeted Fusion Biopsy in Prostate Cancer\u003cb\u003e.- \u003c\/b\u003e24. Optimizing biopsy core quality for diagnosis\u003cb\u003e.-\u003c\/b\u003e \u003cb\u003ePart VI.  Patient Selection and Ablation Treatment Schema.-\u003c\/b\u003e\u003cb\u003e \u003c\/b\u003e25. Patient Selection: What Tumors Should Be Treated Based on Grade, Size, Location, Genetics and Risk Category?\u003cb\u003e.-\u003c\/b\u003e 26. Definitions and Common Terminology for Focal Prostate Ablation\u003cb\u003e.-\u003c\/b\u003e 27. Focal Therapy for Anterior Cancers\u003cb\u003e.-\u003c\/b\u003e 28. Office-based Outpatient Focal Therapy\u003cb\u003e.-\u003c\/b\u003e \u003cb\u003ePart VII.  Transperineal Technologies for Focal Therapy.- \u003c\/b\u003e29. Focal Brachytherapy and IMRT\u003cb\u003e.- \u003c\/b\u003e30. In-bore Transperineal MRI-Guided Laser Ablation\u003cb\u003e.-\u003c\/b\u003e 31. Focal Cryoablation\u003cb\u003e.-\u003c\/b\u003e 32. Irreversible Electroporation for Partial Gland Ablation: Clinical Application and Outcomes\u003cb\u003e.-\u003c\/b\u003e 33. Photodynamic Therapy\u003cb\u003e.-\u003c\/b\u003e \u003cb\u003ePart VIII.  Transurethral Technologies for Focal Therapy.- \u003c\/b\u003e34. Role of TULSA as a Focal Therapy in Prostate Cancer\u003cb\u003e.-\u003c\/b\u003e 35. Transurethral Vapor Ablation in Prostate Cancer\u003cb\u003e.- \u003c\/b\u003e\u003cb\u003ePart IX.  Transrectal Technologies for Focal Therapy.-\u003c\/b\u003e\u003cb\u003e \u003c\/b\u003e36. Robotic High-Intensity Focused Ultrasound\u003cb\u003e.-\u003c\/b\u003e 37. Transrectal laser ablation of prostate cancer\u003cb\u003e.- Part X.  Post-treatment Assessment of Focal Therapy Outcomes.-\u003c\/b\u003e\u003cb\u003e \u003c\/b\u003e38. Role of Prostate MRI for Post-treatment Assessment and Surveillance\u003cb\u003e.-\u003c\/b\u003e 39. Measuring patient-based outcomes: setting realistic expectations when balancing functional outcomes with cancer control\u003cb\u003e.- \u003c\/b\u003e40. Assessing Functional Outcomes after Focal Therapy\u003cb\u003e.-\u003c\/b\u003e 41. Biochemical Assessment of Cancer Outcomes following Focal Therapy\u003cb\u003e.- \u003c\/b\u003e42. Pathologic Assessment and Implications following Prostate Focal Therapy\u003cb\u003e.-\u003c\/b\u003e 43. Salvage Options after Focal Therapy Recurrence\u003cb\u003e.-\u003c\/b\u003e \u003cb\u003ePart XI. Looking forward\u003c\/b\u003e\u003cb\u003e.- \u003c\/b\u003e44. Design of Payment and Reimbursement Strategies for Focal Therapy for Acceptance in Value Based Care Models\u003cb\u003e.-\u003c\/b\u003e 45. The Horizon: Future of Focal Therapy in Prostate Cancer. \u003c\/p\u003e","brand":"Springer","offers":[{"title":"Default Title","offer_id":53516347474263,"sku":"9783031667534","price":161.99,"currency_code":"GBP","in_stock":true}],"url":"https:\/\/bookcurl.com\/products\/imaging-and-focal-therapy-of-early-prostate-cancer-9783031667534","provider":"Book Curl","version":"1.0","type":"link"}